tiprankstipranks
First Tracks Biotherapeutics Inc (TRAX)
NASDAQ:TRAX
US Market
TRAX
First Tracks Biotherapeutics Inc
RESEARCH TOOLSreports
Want to see TRAX full AI Analyst Report?

First Tracks Biotherapeutics Inc (TRAX) Stock Forecast & Price Target

6 Followers
See the Price Targets and Ratings of:

TRAX Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
First
Tracks Biotherapeutics Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TRAX Stock 12 Month Forecast

Average Price Target

$38.50
Based on 6 Wall Street analysts offering 12 month price targets for First Tracks Biotherapeutics Inc in the last 3 months. The average price target is 38.50 with a high forecast of 54.00 and a low forecast of 30.00. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"18","55":"55","27.25":"27.3","36.5":"36.5","45.75":"45.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">38.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,27.25,36.5,45.75,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.38,24.81230769230769,27.244615384615383,29.676923076923075,32.10923076923077,34.54153846153846,36.973846153846154,39.40615384615384,41.83846153846154,44.27076923076923,46.70307692307692,49.13538461538461,51.56769230769231,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.38,23.619999999999997,24.86,26.099999999999998,27.34,28.58,29.82,31.06,32.3,33.54,34.78,36.019999999999996,37.26,{"y":38.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.38,22.966153846153844,23.552307692307693,24.138461538461538,24.724615384615383,25.310769230769232,25.896923076923077,26.483076923076922,27.06923076923077,27.655384615384616,28.24153846153846,28.82769230769231,29.413846153846155,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.38,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target54.00Average Price Target38.50Lowest Price Target30.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on TRAX
Etzer Darout
Barclays
Barclays
$40
Buy
―
Reiterated
05/15/26
First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Barclays
Wedbush Analyst forecast on TRAX
Martin Fan
Wedbush
Wedbush
$30
Buy
―
Reiterated
05/15/26
Analysts' Top Healthcare Picks: Monopar Therapeutics Inc (MNPR), First Tracks Biotherapeutics Inc (TRAX)
H.C. Wainwright Analyst forecast on TRAX
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$30
Buy
―
Reiterated
05/15/26
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway
Piper Sandler Analyst forecast on TRAX
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$54
Buy
―
Initiated
05/04/26
First Tracks Biotherapeutics initiated with an Overweight at Piper SandlerFirst Tracks Biotherapeutics initiated with an Overweight at Piper Sandler
Leerink Partners Analyst forecast on TRAX
David Risinger
Leerink Partners
Leerink Partners
$46
Buy
―
Initiated
04/24/26
TRAX: Event-Driven Immunology Catalyst Play With Differentiated Pipeline and Valuation Upside Supporting Buy Rating
J.P. Morgan Analyst forecast on TRAX
Anupam Rama
J.P. Morgan
J.P. Morgan
$31
Buy
―
Initiated
04/23/26
First Tracks Biotherapeutics initiated with an Overweight at JPMorganFirst Tracks Biotherapeutics initiated with an Overweight at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on TRAX
Etzer Darout
Barclays
Barclays
$40
Buy
―
Reiterated
05/15/26
First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Barclays
Wedbush Analyst forecast on TRAX
Martin Fan
Wedbush
Wedbush
$30
Buy
―
Reiterated
05/15/26
Analysts' Top Healthcare Picks: Monopar Therapeutics Inc (MNPR), First Tracks Biotherapeutics Inc (TRAX)
H.C. Wainwright Analyst forecast on TRAX
Emily Bodnar
H.C. Wainwright
H.C. Wainwright
$30
Buy
―
Reiterated
05/15/26
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway
Piper Sandler Analyst forecast on TRAX
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$54
Buy
―
Initiated
05/04/26
First Tracks Biotherapeutics initiated with an Overweight at Piper SandlerFirst Tracks Biotherapeutics initiated with an Overweight at Piper Sandler
Leerink Partners Analyst forecast on TRAX
David Risinger
Leerink Partners
Leerink Partners
$46
Buy
―
Initiated
04/24/26
TRAX: Event-Driven Immunology Catalyst Play With Differentiated Pipeline and Valuation Upside Supporting Buy Rating
J.P. Morgan Analyst forecast on TRAX
Anupam Rama
J.P. Morgan
J.P. Morgan
$31
Buy
―
Initiated
04/23/26
First Tracks Biotherapeutics initiated with an Overweight at JPMorganFirst Tracks Biotherapeutics initiated with an Overweight at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Sector
Find stocks in the sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering First Tracks Biotherapeutics Inc

3 Months
xxx
Success Rate
0/1 ratings generated profit
0%
Average Return
0.00%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
0/1 ratings generated profit
0%
Average Return
0.00%
Copying David Risinger's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
2 Years
xxx
Success Rate
0/1 ratings generated profit
0%
Average Return
0.00%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TRAX Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
4
8
Buy
0
0
0
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
5
9
In the current month, TRAX has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TRAX average Analyst price target in the past 3 months is 38.50.
Each month's total comprises the sum of three months' worth of ratings.

TRAX Financial Forecast

TRAX Earnings Forecast

Next quarter’s earnings estimate for TRAX is -1.05 with a range of -1.45 to -0.60. The previous quarter’s EPS was -1.00. TRAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year TRAX has its overall industry.
Next quarter’s earnings estimate for TRAX is -1.05 with a range of -1.45 to -0.60. The previous quarter’s EPS was -1.00. TRAX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year TRAX has its overall industry.
No data currently available

TRAX Sales Forecast

Next quarter’s sales forecast for TRAX is 0.00 with a range of 0.00 to 0.00. The previous quarter’s sales results were ―. TRAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year TRAX has its overall industry.
Next quarter’s sales forecast for TRAX is 0.00 with a range of 0.00 to 0.00. The previous quarter’s sales results were ―. TRAX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year TRAX has its overall industry.

TRAX Stock Forecast FAQ

What is TRAX’s average 12-month price target, according to analysts?
Based on analyst ratings, First Tracks Biotherapeutics Inc’s 12-month average price target is 38.50.
    What is TRAX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for TRAX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is TRAX a Buy, Sell or Hold?
        First Tracks Biotherapeutics Inc has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
          What is First Tracks Biotherapeutics Inc’s price target?
          The average price target for First Tracks Biotherapeutics Inc is 38.50. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is 54.00 ,the lowest forecast is 30.00. The average price target represents N/A Increase from the current price of N/A.
            What do analysts say about First Tracks Biotherapeutics Inc?
            First Tracks Biotherapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
              How can I buy shares of TRAX?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.